Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

Ryan Orgel; Daniel Wojdyla; David Huberman; Jonathan L Halperin; Günter Breithardt; Daniel E Singer; Keith A A Fox; Graeme J Hankey; Kenneth W Mahaffey; W Schuyler Jones; Manesh R Patel

doi:10.1161/CIRCOUTCOMES.116.003520

Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

Ryan Orgel, Daniel Wojdyla, David Huberman, Jonathan L Halperin, Günter Breithardt, Daniel E Singer, Keith A A Fox, Graeme J Hankey, Kenneth W Mahaffey, W Schuyler Jones, Manesh R Patel

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Circulation: Cardiovascular Quality and Outcomes
Volume	10
Issue number	5
DOIs	https://doi.org/10.1161/CIRCOUTCOMES.116.003520
Publication status	Published - 11 May 2017

Keywords / Materials (for Non-textual outputs)

Journal Article

Access to Document

10.1161/CIRCOUTCOMES.116.003520

Cite this

Orgel, R., Wojdyla, D., Huberman, D., Halperin, J. L., Breithardt, G., Singer, D. E., Fox, K. A. A., Hankey, G. J., Mahaffey, K. W., Jones, W. S., & Patel, M. R. (2017). Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Circulation: Cardiovascular Quality and Outcomes, 10(5). https://doi.org/10.1161/CIRCOUTCOMES.116.003520

Orgel, Ryan ; Wojdyla, Daniel ; Huberman, David et al. / Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation : Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). In: Circulation: Cardiovascular Quality and Outcomes. 2017 ; Vol. 10, No. 5.

@article{4e5abc01c0e34ab4800e95eb584458fb,

title = "Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)",

keywords = "Journal Article",

author = "Ryan Orgel and Daniel Wojdyla and David Huberman and Halperin, {Jonathan L} and G{\"u}nter Breithardt and Singer, {Daniel E} and Fox, {Keith A A} and Hankey, {Graeme J} and Mahaffey, {Kenneth W} and Jones, {W Schuyler} and Patel, {Manesh R}",

year = "2017",

month = may,

day = "11",

doi = "10.1161/CIRCOUTCOMES.116.003520",

language = "English",

volume = "10",

journal = "Circulation: Cardiovascular Quality and Outcomes",

issn = "1941-7705",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

Orgel, R, Wojdyla, D, Huberman, D, Halperin, JL, Breithardt, G, Singer, DE, Fox, KAA, Hankey, GJ, Mahaffey, KW, Jones, WS & Patel, MR 2017, 'Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)', Circulation: Cardiovascular Quality and Outcomes, vol. 10, no. 5. https://doi.org/10.1161/CIRCOUTCOMES.116.003520

Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). / Orgel, Ryan; Wojdyla, Daniel; Huberman, David et al.
In: Circulation: Cardiovascular Quality and Outcomes, Vol. 10, No. 5, 11.05.2017.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation

T2 - Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

AU - Orgel, Ryan

AU - Wojdyla, Daniel

AU - Huberman, David

AU - Halperin, Jonathan L

AU - Breithardt, Günter

AU - Singer, Daniel E

AU - Fox, Keith A A

AU - Hankey, Graeme J

AU - Mahaffey, Kenneth W

AU - Jones, W Schuyler

AU - Patel, Manesh R

PY - 2017/5/11

Y1 - 2017/5/11

KW - Journal Article

U2 - 10.1161/CIRCOUTCOMES.116.003520

DO - 10.1161/CIRCOUTCOMES.116.003520

M3 - Article

C2 - 28495674

SN - 1941-7705

VL - 10

JO - Circulation: Cardiovascular Quality and Outcomes

JF - Circulation: Cardiovascular Quality and Outcomes

IS - 5

ER -

Orgel R, Wojdyla D, Huberman D, Halperin JL, Breithardt G, Singer DE et al. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Circulation: Cardiovascular Quality and Outcomes. 2017 May 11;10(5). doi: 10.1161/CIRCOUTCOMES.116.003520